Correspondingly, we found that combination treatment with BYL719 and KTN3379 was able to effectively suppress HNSCC growth in vitro and in vivo along with biomolecular activation of PI3K, AKT, and S6 in HNSCC16–19. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.